Diagnosis of invasive fungal disease in coronavirus disease 2019: approaches and pitfalls

• Published in: Current opinion in infectious diseases Vol. 34; no. 6; pp. 573 - 580
• Main Author: White, P. Lewis
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-12-2021
• Subjects: ANTIMICROBIAL AGENTS: BACTERIAL/FUNGAL: Edited by Monica A. Slavin; COVID-19; Humans; Invasive Fungal Infections - diagnosis; Mucormycosis; Mycoses; SARS-CoV-2
• ISSN: 0951-7375; 1473-6527
• DOI: 10.1097/QCO.0000000000000791

This review will comment on the current knowledge for the diagnosis of the main causes of COVID-19-associated invasive fungal disease (IFD); it will discuss the optimal strategies and limitations and wherever available, will describe international recommendations.
A range of secondary IFDs complicating COVID-19 infection have been described and while COVID-19-associated pulmonary aspergillosis was predicted, the presentation of significant numbers of COVID-19-associated candidosis and COVID-19-associated mucormycosis was somewhat unexpected. Given the range of IFDs and prolonged duration of risk, diagnostic strategies need to involve multiple tests for detecting and differentiating various causes of IFD. Although performance data for a range of tests to diagnose COVID-19-associated pulmonary aspergillosis is emerging, the performance of tests to diagnose other IFD is unknown or based on pre-COVID performance data.
Because of the vast numbers of COVID-19 infections, IFD in COVID-19 critical-care patients represents a significant burden of disease, even if incidences are less than 5%. Optimal diagnosis of COVID-19-associated IFD requires a strategic approach. The pandemic has highlighted the potential impact of IFD outside of the typical high-risk clinical cohorts, given the ever-increasing population at risk of IFD and enhanced surveillance of fungal infections is required.